Market Overview:
The global cancer/tumor profiling and pathways market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The market growth is attributed to the increasing incidence of cancer, technological advancements in tumor profiling and pathways analysis, and rising demand for personalized medicine. The global cancer/tumor profiling and pathways market by type is segmented into immunoassays, next generation sequencing (NGS), polymerase chain reaction (PCR), in-situ hybridization (ISH), microarrays, mass spectrometry, and others. The immunoassays segment accounted for the largest share of the global cancer/tumor profiling and pathways market in 2017 owing to its high accuracy and reliability. However, the NGS segment is expected to grow at the highest CAGR during the forecast period due to its ability to detect low-frequency variants present in tumors. The global cancer/tumor profiling and pathways market by application is divided into research applicationsand clinical applications.
Product Definition:
Cancer/tumor profiling is the study of the genetic and molecular features of cancer cells in order to identify potential targets for therapy. This information can be used to develop personalized treatments for individual patients. Pathways are the networks of proteins that interact with one another to carry out complex biological processes. Cancer/tumor profiling and pathways can be used to identify which proteins are involved in cancer development and progression, and may serve as targets for therapy.
Immunoassays:
Immunoassays are a group of techniques that involve the use of antibodies and their binding partners to detect or measure substances in biological fluids. Immunoassay techniques include Enzyme-linked Immunosorbent Assay (ELISA), Micro Enzyme Uptake High Throughput Screening (MOUTHS), immunoprecipitation, western blotting, flow cytometry, and radioimmuno-precipitation.
Next Generation Sequencing (NGS):
Next Generation Sequencing (NGS) is a technology that involves the use of high-throughput sequencers to analyze and sequence DNA. It allows comprehensive sequencing of all human genome in a single run which takes days as opposed to conventional methods, which take weeks or months to finish. Next generation sequencing has been applied in various areas such as genetic testing, disease mapping & identification, biomarker discovery & development and drug discovery among others.
Application Insights:
The research segment dominated the market in 2017 and accounted for a revenue share of more than 60%. This is attributed to the rising number of R&D initiatives pertaining to cancer/tumor profiling and pathways. For instance, in September 2016, an alliance between Merck KGaA, Darmstadt, Germany; MSD Pharmaceuticals Inc., New York; and Pfizer Inc., New York was signed for development of novel immunotherapies against solid tumors. The clinical development phase of this alliance project is expected to last for around 3 years.
Furthermore, several companies including Illumina are investing heavily in the development of NGS-based panels that can be used as a standard diagnostic tool across various tumor types at varying stages during clinical trials. Such initiatives by prominent players are anticipated to boost market growth over the forecast period.
On the other hand, while considering new drug applications with FDA (U.S.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of cancer research organizations, such as Cancer Research Institute, American Cancer Society and others. These organizations are engaged in conducting various types of studies related to cancer and tumor profiling using immunoassays, NGS techniques, PCR analysis & others. Thus, they are contributing significantly to the growth of this vertical in this region.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to increasing investments by governments & private entities for R&D activities relatedto oncology diagnostics coupled with rising healthcare expenditure levels in emerging economies like India and China.
Growth Factors:
- Increasing incidence of cancer and tumor across the globe
- Rising demand for personalized medicine and targeted therapies
- Proliferation of next-generation sequencing technologies
- Growing investments in cancer research by public and private organizations
- Emergence of precision oncology as a promising treatment paradigm
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer/Tumor Profiling and Pathways Market Research Report
By Type
Immunoassays, Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Microarrays, Mass Spectrometry, Others
By Application
Research, Clinical
By Companies
Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Sysmex Corporation (Japan)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
121
Number of Tables & Figures
85
Customization Available
Yes, the report can be customized as per your need.
Global Cancer/Tumor Profiling and Pathways Market Report Segments:
The global Cancer/Tumor Profiling and Pathways market is segmented on the basis of:
Types
Immunoassays, Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In-Situ Hybridization (ISH), Microarrays, Mass Spectrometry, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research, Clinical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Illumina, Inc. (US)
- QIAGEN N.V. (Germany)
- NeoGenomics Laboratories, Inc. (US)
- HTG Molecular Diagnostics, Inc. (US)
- Sysmex Corporation (Japan)
Highlights of The Cancer/Tumor Profiling and Pathways Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunoassays
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- In-Situ Hybridization (ISH)
- Microarrays
- Mass Spectrometry
- Others
- By Application:
- Research
- Clinical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer/Tumor Profiling and Pathways Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer/tumor profiling and pathways is a research field that uses genomic, proteomic, and epigenetic data to identify molecular signatures of cancer. These signatures can then be used to guide the development of new treatments or biomarkers for early detection.
Some of the major companies in the cancer/tumor profiling and pathways market are Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Sysmex Corporation (Japan).
The cancer/tumor profiling and pathways market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer/Tumor Profiling and Pathways Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer/Tumor Profiling and Pathways Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer/Tumor Profiling and Pathways Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer/Tumor Profiling and Pathways Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer/Tumor Profiling and Pathways Market Size & Forecast, 2018-2028
4.5.1 Cancer/Tumor Profiling and Pathways Market Size and Y-o-Y Growth
4.5.2 Cancer/Tumor Profiling and Pathways Market Absolute $ Opportunity
Chapter 5 Global Cancer/Tumor Profiling and Pathways Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancer/Tumor Profiling and Pathways Market Size Forecast by Type
5.2.1 Immunoassays
5.2.2 Next Generation Sequencing (NGS)
5.2.3 Polymerase Chain Reaction (PCR)
5.2.4 In-Situ Hybridization (ISH)
5.2.5 Microarrays
5.2.6 Mass Spectrometry
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancer/Tumor Profiling and Pathways Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancer/Tumor Profiling and Pathways Market Size Forecast by Applications
6.2.1 Research
6.2.2 Clinical
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer/Tumor Profiling and Pathways Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer/Tumor Profiling and Pathways Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancer/Tumor Profiling and Pathways Analysis and Forecast
9.1 Introduction
9.2 North America Cancer/Tumor Profiling and Pathways Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancer/Tumor Profiling and Pathways Market Size Forecast by Type
9.6.1 Immunoassays
9.6.2 Next Generation Sequencing (NGS)
9.6.3 Polymerase Chain Reaction (PCR)
9.6.4 In-Situ Hybridization (ISH)
9.6.5 Microarrays
9.6.6 Mass Spectrometry
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancer/Tumor Profiling and Pathways Market Size Forecast by Applications
9.10.1 Research
9.10.2 Clinical
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancer/Tumor Profiling and Pathways Analysis and Forecast
10.1 Introduction
10.2 Europe Cancer/Tumor Profiling and Pathways Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancer/Tumor Profiling and Pathways Market Size Forecast by Type
10.6.1 Immunoassays
10.6.2 Next Generation Sequencing (NGS)
10.6.3 Polymerase Chain Reaction (PCR)
10.6.4 In-Situ Hybridization (ISH)
10.6.5 Microarrays
10.6.6 Mass Spectrometry
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancer/Tumor Profiling and Pathways Market Size Forecast by Applications
10.10.1 Research
10.10.2 Clinical
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancer/Tumor Profiling and Pathways Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancer/Tumor Profiling and Pathways Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancer/Tumor Profiling and Pathways Market Size Forecast by Type
11.6.1 Immunoassays
11.6.2 Next Generation Sequencing (NGS)
11.6.3 Polymerase Chain Reaction (PCR)
11.6.4 In-Situ Hybridization (ISH)
11.6.5 Microarrays
11.6.6 Mass Spectrometry
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancer/Tumor Profiling and Pathways Market Size Forecast by Applications
11.10.1 Research
11.10.2 Clinical
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancer/Tumor Profiling and Pathways Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancer/Tumor Profiling and Pathways Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancer/Tumor Profiling and Pathways Market Size Forecast by Type
12.6.1 Immunoassays
12.6.2 Next Generation Sequencing (NGS)
12.6.3 Polymerase Chain Reaction (PCR)
12.6.4 In-Situ Hybridization (ISH)
12.6.5 Microarrays
12.6.6 Mass Spectrometry
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancer/Tumor Profiling and Pathways Market Size Forecast by Applications
12.10.1 Research
12.10.2 Clinical
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancer/Tumor Profiling and Pathways Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancer/Tumor Profiling and Pathways Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancer/Tumor Profiling and Pathways Market Size Forecast by Type
13.6.1 Immunoassays
13.6.2 Next Generation Sequencing (NGS)
13.6.3 Polymerase Chain Reaction (PCR)
13.6.4 In-Situ Hybridization (ISH)
13.6.5 Microarrays
13.6.6 Mass Spectrometry
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancer/Tumor Profiling and Pathways Market Size Forecast by Applications
13.10.1 Research
13.10.2 Clinical
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer/Tumor Profiling and Pathways Market: Competitive Dashboard
14.2 Global Cancer/Tumor Profiling and Pathways Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Illumina, Inc. (US)
14.3.2 QIAGEN N.V. (Germany)
14.3.3 NeoGenomics Laboratories, Inc. (US)
14.3.4 HTG Molecular Diagnostics, Inc. (US)
14.3.5 Sysmex Corporation (Japan)
